You are viewing a preview of...

Antibody-Mediated Blockade of FCRL6

FCRL6 and LAG-3 act as receptors for MHC-II, suppressing antigen presentation and cytotoxic immune response, for numerous tumor types

Background

Programmed death-1 (PD-1) is a checkpoint protein expressed on T-cells and plays an important role in the regulation of immune response. PD-1 acts by recognizing and binding to its ligand (PD-L1) expressed on dendritic cells. This induces a signal to T-cells not to attack the other cells. The interaction between PD-1 and PD-L1 allows for selective activation of cytotoxic immune response and reduces risk of chronic autoimmune inflammation. Normally, tumor cells express mutated antigens which dendritic cells capture then use to prime and activate T-cells. Activated T-cells then locate the tumor expressing the mutated antigen and release cytotoxins causing apoptosis of the tumor cells.

Interestingly, tumor cells may evade immune system response by overexpressing PD-L1, thereby suppressing the activation

Log in or create a free account to continue reading